Skip to main content
  • Neuroglobin and Nogo-A as Biomarkers for the Severity and Prognosis of Traumatic Brain Injury

    Final Number:

    Hao Chen MD; Hengli Tian

    Study Design:
    Laboratory Investigation

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2018 Annual Meeting - Late Breaking Science

    Introduction: Neuroglobin has been described as a neuroprotective agent when overexpressed in traumatic brain injury (TBI), Nogo-A has also shown an important role in axonal remodeling after TBI, and therefore they have the potential to impact outcomes after TBI. Thus, we investigated early changes in the concentrations of serum neuroglobin and Nogo-A after TBI and evaluated the relations of both neuroglobin and Nogo-A to injury severity and prognosis.

    Methods: Thirty-four patients with TBI were included in this study. Serum samples were obtained on admission and at 6, 12, 24, 48, 72, and 96 h after injury. Serum concentrations of neuroglobin and Nogo-A were measured by using the enzyme linked immunosorbent assay (ELISA) method and comparative analysis combined with Glasgow Coma Scale (GCS) scores and the 6-month prognosis of the patients were performed. Receiver operating characteristic (ROC) curve was used to appraise the value of serum neuroglobin and Nogo-A levels in predicting the prognosis of patients with TBI.

    Results: The serum neuroglobin concentrations increased for 48 h after injury and sharply decreased thereafter, whereas serum concentrations of Nogo-A increased and reached a peak at 72 h, after which it decreased gradually. The mean peak serum concentrations of neuroglobin and Nogo-A in patients with severe TBI was significantly higher than that in patients with mild TBI (P<0.05). Significant correlations were found between peak serum neuroglobin and Nogo-A concentrations and a patient’s GCS score on admission (P<0.001). Compared with the better prognosis group at 6 months after injury, the mean peak serum neuroglobin and Nogo-A concentrations were both significantly higher in patients with an unfavorable outcome (P<0.05). ROC curve analysis suggested that the serum Nogo-A concentration had a significantly better predictive power for poor prognosis.

    Conclusions: Neuroglobin and Nogo-A levels in serum of patients with TBI increased obviously after injury, and were suggested as biomarkers for predicting brain injury severity and poor prognosis.

    Patient Care: This observation supports the hypothesis that neuroglobin and Nogo-A play an important role in TBI, possibly involving development of secondary brain damage. Our results also indicated that the upregulation of neuroglobin and Nogo-A correlated to injury severity and prognosis of TBI, and thus has important implications for the future treatment.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) Describe the importance of evaluating the severity and predicting the prognosis of traumatic brain injury, 2) Discuss, in small groups, 3) Identify an effective treatment for traumatic brain injury.


We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy